Loading viewer...
investor_presentation
Format: PDF investor_presentation
1 ©2021 KARYOPHARM THERAPEUTICS INC. Business Highlights & Second Quarter 2021 Financial Results August 5, 2021
1 ©2021 KARYOPHARM THERAPEUTICS INC.
Business Highlights &
August 5, 2021 2 ©2021 KARYOPHARM THERAPEUTICS INC.
•Stephen Mitchener, PharmD
Chief Business Officer
•Sharon Shacham, PhD
Chief Scientific OfficerOn Today’s Call
Joseph Rayne, Argot Partners
Richard Paulson, President and Chief Executive Officer
•Commercial Highlights
Sohanya Cheng, SVP, Sales and Commercial Operations
•Clinical Pipeline Updates
Jatin Shah, MD, Chief Medical Officer
•Financial Summary and Guidance
Michael Mason, Chief Financial Officer
Richard Paulson, President and Chief Executive Officer
•Q&A Session 3 ©2021 KARYOPHARM THERAPEUTICS INC. Forward -looking Statements and Other Important Information
This presentation contains forward -looking statements within themeaning ofThe Private Securities Litigation Reform Actof1995 .Such forward -looking statements include those regarding Karyopharm’s
guidance onits2021 non-GAAP research anddevelopment andselling, general andadministrative expenses ;Karyopharm’s expected cash runway ;expectations andplans relating toXPOVIO forthetreatment
ofadult patients withrelapsed orrefractory multiple myeloma orrelapsed orrefractory diffuse large B-celllymphoma andother hematologic malignancies andsolid tumors ;commercialization ofXPOVIO orany
ofitsdrug candidates andthecommercial performance ofXPOVIO ;submissions to,andthereview andpotential approval ofselinexor by,regulatory authorities, including theCompany’s regulatory strategy,
theanticipated availability ofdata tosupport such submissions, timing ofsuch submissions andactions byregulatory authorities andthepotential availability ofaccelerated approval pathways ;theexpected
design oftheCompany’s clinical trials ;andthetherapeutic potential ofandpotential clinical development plans forKaryopharm's drug candidates, especially selinexor .Such statements aresubject tonumerous
important factors, risks anduncertainties, many ofwhich arebeyond Karyopharm's control, thatmay cause actual events orresults todiffer materially from Karyopharm's current expectations .Forexample,
there canbenoguarantee thatKaryopharm willsuccessfully commercialize XPOVIO ;thatregulators willgrant confirmatory approval intheEuropean Union based ontheBOSTON study inadult patients with
multiple myeloma ;orthat anyofKaryopharm’s drug candidates, including selinexor, willsuccessfully complete necessary clinical development phases orthat development ofanyofKaryopharm’s drug
candidates willcontinue .Further, there canbenoguarantee that anypositive developments inthedevelopment orcommercialization ofKaryopharm’s drug candidate portfolio willresult instock price
appreciation .Management’s expectations and, therefore, anyforward -looking statements inthispress release could also beaffected byrisks anduncertainties relating toanumber ofother factors, including the
following :theriskthattheCOVID -19pandemic could disrupt Karyopharm’s business more severely than itcurrently anticipates, including bynegatively impacting sales ofXPOVIO, interrupting ordelaying
Preview truncated — download the full document for the complete content.
conference
34 Pages
investor_presentation
65 Pages
National Fuel Gas Company